Cargando…
Five years experience on 3,4-diaminopyridine phosphate in Lambert–Eaton syndrome: Case reports
RATIONALE: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. PATIENT CONCERNS: Patients have...
Autores principales: | Portaro, Simona, Brizzi, Teresa, Sinicropi, Stefano, Cacciola, Alberto, De Cola, Maria Cristina, Bramanti, Alessia, Milardi, Demetrio, Lupica, Antonino, Bramanti, Placido, Toscano, Antonio, Rodolico, Carmelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617689/ https://www.ncbi.nlm.nih.gov/pubmed/28930822 http://dx.doi.org/10.1097/MD.0000000000007839 |
Ejemplares similares
-
3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia
por: Sanders, Donald B., et al.
Publicado: (2018) -
Population Pharmacokinetics/Pharmacodynamics of 3,4‐Diaminopyridine Free Base in Patients With Lambert‐Eaton Myasthenia
por: Thakkar, Nilay, et al.
Publicado: (2017) -
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials
por: Zhang, Na, et al.
Publicado: (2021) -
Ophthalmoplegia associated with lung adenocarcinoma in a patient with the Lambert–Eaton myasthenic syndrome: A case report
por: Tang, Yufeng, et al.
Publicado: (2017) -
Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita: A case report on a potential treatment option
por: Portaro, Simona, et al.
Publicado: (2020)